Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer

Volker R. Jacobs; Doris Augustin; Arthur Wischnik; Marion Kiechle; Cornelia Höss; Oliver Steinkohl; Brigitte Rack; Thomas Kapitza; Peter Krase

doi:10.1016/j.breast.2013.04.009

Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer

Volker R. Jacobs, Doris Augustin, Arthur Wischnik, Marion Kiechle, Cornelia Höss, Oliver Steinkohl, Brigitte Rack, Thomas Kapitza, Peter Krase

Chair of Gynaecology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Biomarkers uPA/PAI-1 as recommended by ASCO and AGO are used in primary breast cancer to avoid unnecessary CTX in medium risk-recurrence patients. This study verified how many CTX cycles and CTX-related direct medication costs can be avoided by uPA/PAI-1 testing.A prospective, non-interventional, multi-center study was performed among six Certified Breast Centers to analyze application of uPA/PAI-1 and consecutive decision-making. CTX avoided were identified and direct costs for CTX, CTX-related concomitant medication and febrile neutropenia (FN) prophylaxis with G-CSF calculated. In n=93 breast cancers n=35 CTX (37.6%) with 210 CTX cycles were avoided according to uPA/PAI-1 test result. uPA/PAI-1 testing saved direct medication costs for CTX of 177,453 €, CTX-related concomitant medication of 27,482 € and FN prophylaxis of 20,599 €, overall 225,534 €. At test costs at 287.50 € uPA/PAI-1 testing resulted in additional costs of 26,737.50 €. uPA/PAI-1 has proven to be cost-effective at a return-on-investment ratio of 8.4:1. Indirect cost savings further increase this ROI. These results support decision-making for cost-effective diagnostics and therapy in breast cancer.

Original language	English
Pages (from-to)	436-443
Number of pages	8
Journal	Breast
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/j.breast.2013.04.009
State	Published - Aug 2013

Keywords

Biomarker
Breast cancer
Clinical cost-effectiveness analysis
Costs
Economics
Prevention of chemotherapy
Quality of life

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2013.04.009

Cite this

@article{82384766e5214c908fd55cafcb089b6b,

title = "Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer",

abstract = "Biomarkers uPA/PAI-1 as recommended by ASCO and AGO are used in primary breast cancer to avoid unnecessary CTX in medium risk-recurrence patients. This study verified how many CTX cycles and CTX-related direct medication costs can be avoided by uPA/PAI-1 testing.A prospective, non-interventional, multi-center study was performed among six Certified Breast Centers to analyze application of uPA/PAI-1 and consecutive decision-making. CTX avoided were identified and direct costs for CTX, CTX-related concomitant medication and febrile neutropenia (FN) prophylaxis with G-CSF calculated. In n=93 breast cancers n=35 CTX (37.6%) with 210 CTX cycles were avoided according to uPA/PAI-1 test result. uPA/PAI-1 testing saved direct medication costs for CTX of 177,453 €, CTX-related concomitant medication of 27,482 € and FN prophylaxis of 20,599 €, overall 225,534 €. At test costs at 287.50 € uPA/PAI-1 testing resulted in additional costs of 26,737.50 €. uPA/PAI-1 has proven to be cost-effective at a return-on-investment ratio of 8.4:1. Indirect cost savings further increase this ROI. These results support decision-making for cost-effective diagnostics and therapy in breast cancer.",

keywords = "Biomarker, Breast cancer, Clinical cost-effectiveness analysis, Costs, Economics, Prevention of chemotherapy, Quality of life",

author = "Jacobs, {Volker R.} and Doris Augustin and Arthur Wischnik and Marion Kiechle and Cornelia H{\"o}ss and Oliver Steinkohl and Brigitte Rack and Thomas Kapitza and Peter Krase",

note = "Funding Information: This study was supported by AOK Bayern, Munich, Germany, a regional health care fund and market leader of Bavaria in Southeastern Germany. The study sponsor was interested in the objective results of this study and had no influence in any form on this manuscript. ",

year = "2013",

month = aug,

doi = "10.1016/j.breast.2013.04.009",

language = "English",

volume = "22",

pages = "436--443",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "4",

}

Jacobs, VR, Augustin, D, Wischnik, A, Kiechle, M, Höss, C, Steinkohl, O, Rack, B, Kapitza, T & Krase, P 2013, 'Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer', Breast, vol. 22, no. 4, pp. 436-443. https://doi.org/10.1016/j.breast.2013.04.009

TY - JOUR

T1 - Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer

AU - Jacobs, Volker R.

AU - Augustin, Doris

AU - Wischnik, Arthur

AU - Kiechle, Marion

AU - Höss, Cornelia

AU - Steinkohl, Oliver

AU - Rack, Brigitte

AU - Kapitza, Thomas

AU - Krase, Peter

N1 - Funding Information: This study was supported by AOK Bayern, Munich, Germany, a regional health care fund and market leader of Bavaria in Southeastern Germany. The study sponsor was interested in the objective results of this study and had no influence in any form on this manuscript.

PY - 2013/8

Y1 - 2013/8

N2 - Biomarkers uPA/PAI-1 as recommended by ASCO and AGO are used in primary breast cancer to avoid unnecessary CTX in medium risk-recurrence patients. This study verified how many CTX cycles and CTX-related direct medication costs can be avoided by uPA/PAI-1 testing.A prospective, non-interventional, multi-center study was performed among six Certified Breast Centers to analyze application of uPA/PAI-1 and consecutive decision-making. CTX avoided were identified and direct costs for CTX, CTX-related concomitant medication and febrile neutropenia (FN) prophylaxis with G-CSF calculated. In n=93 breast cancers n=35 CTX (37.6%) with 210 CTX cycles were avoided according to uPA/PAI-1 test result. uPA/PAI-1 testing saved direct medication costs for CTX of 177,453 €, CTX-related concomitant medication of 27,482 € and FN prophylaxis of 20,599 €, overall 225,534 €. At test costs at 287.50 € uPA/PAI-1 testing resulted in additional costs of 26,737.50 €. uPA/PAI-1 has proven to be cost-effective at a return-on-investment ratio of 8.4:1. Indirect cost savings further increase this ROI. These results support decision-making for cost-effective diagnostics and therapy in breast cancer.

AB - Biomarkers uPA/PAI-1 as recommended by ASCO and AGO are used in primary breast cancer to avoid unnecessary CTX in medium risk-recurrence patients. This study verified how many CTX cycles and CTX-related direct medication costs can be avoided by uPA/PAI-1 testing.A prospective, non-interventional, multi-center study was performed among six Certified Breast Centers to analyze application of uPA/PAI-1 and consecutive decision-making. CTX avoided were identified and direct costs for CTX, CTX-related concomitant medication and febrile neutropenia (FN) prophylaxis with G-CSF calculated. In n=93 breast cancers n=35 CTX (37.6%) with 210 CTX cycles were avoided according to uPA/PAI-1 test result. uPA/PAI-1 testing saved direct medication costs for CTX of 177,453 €, CTX-related concomitant medication of 27,482 € and FN prophylaxis of 20,599 €, overall 225,534 €. At test costs at 287.50 € uPA/PAI-1 testing resulted in additional costs of 26,737.50 €. uPA/PAI-1 has proven to be cost-effective at a return-on-investment ratio of 8.4:1. Indirect cost savings further increase this ROI. These results support decision-making for cost-effective diagnostics and therapy in breast cancer.

KW - Biomarker

KW - Breast cancer

KW - Clinical cost-effectiveness analysis

KW - Costs

KW - Economics

KW - Prevention of chemotherapy

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84879781104&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.04.009

DO - 10.1016/j.breast.2013.04.009

M3 - Article

C2 - 23643802

AN - SCOPUS:84879781104

SN - 0960-9776

VL - 22

SP - 436

EP - 443

JO - Breast

JF - Breast

IS - 4

ER -

Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this